The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwMDS 2025 | Advances in the treatment of LR-MDS: luspatercept combinations, the use of imetelstat & more
In this discussion, experts Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, Mikkael Sekeres, MD, MS, Sylvester Comprehensive Cancer Center, Miami, FL, and Lionel Ades, MD, PhD, Hospital Saint-Louis, Paris, France, discuss recent advances in the treatment and management of lower-risk myelodysplastic syndromes (LR-MDS). They highlight the COMBOLA study (NCT05181735) and discuss the use of imetelstat in this patient population. This discussion took place at the 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) 2025, held in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
